MicroPort Scientific : Hercules® Stent Graft and Delivery System of MicroPort® Endova...

Shanghai, China - On December 31, Hercules Stent Graft and Delivery System, in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ('MicroPort Endovascular'), was awarded 2016 Shanghai Top-Brand Product, according to a list released by Shanghai Top Brand Recommendation Committee of Shanghai Municipal Bureau of Quality and Technical Supervision. The award is to honor well-known products and brands with industry-leading position, high customer satisfaction and great development potential.

Shanghai Top-Brand Products are selected by Shanghai Top Brand Recommendation Committee of Shanghai Municipal Bureau of Quality and Technical Supervision, based on the company's core competitiveness, industry position, strategy of building independent brands, innovation sustainability, R&D input, innovative development strategy, as well as the role it plays in driving the industry development. This honorable title signifies government recognition in the brand image of Hercules Stent Graft and Delivery System as well as the overall performance of MicroPort Endovascular.

Hercules Stent Graft and Delivery System is one of the core products in-house developed by MicroPort Endovascular. Hercules products align with China and Shanghai's development policies of the bioengineering and pharmaceutical industry, and were listed as Shanghai's first batch of independently innovated products. Hercules products include Hercules Thoracic Aortic Aneurysm Stent Graft and Delivery System and Hercules Abdominal Aortic Aneurysm Stent Graft and Delivery System, both are first of its kind in China, respectively designed for the treatment of thoracic aortic aneurysm and abdominal aortic aneurysm. Since market launch, Hercules products demonstrated outstanding clinical performance and have saved around 30,000 patients with aortic diseases.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:

Sophie Wei Senior Corporate Culture Manager Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-8018 Email: [e-mail]